Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) announced its earnings results on Tuesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.02), Briefing.com reports. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. The company’s revenue was up .0% on a year-over-year basis.

Aurinia Pharmaceuticals (NASDAQ:AUPH) traded down $0.15 during trading hours on Tuesday, hitting $5.62. 729,100 shares of the stock traded hands, compared to its average volume of 3,840,873. Aurinia Pharmaceuticals has a one year low of $2.02 and a one year high of $10.54.

A number of equities analysts recently issued reports on the stock. Vetr lowered shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 target price for the company. in a research report on Wednesday, September 6th. Seaport Global Securities reiterated a “buy” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, October 6th. BidaskClub lowered shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Tuesday, August 15th. Finally, Leerink Swann increased their target price on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the company an “outperform” rating in a research report on Monday, October 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $10.79.

TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/11/14/aurinia-pharmaceuticals-inc-auph-announces-earnings-results-misses-estimates-by-0-02-eps.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Earnings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.